Global Human Respiratory Syncytial Virus Drugs Market 2016-2020
SKU ID :TNV-10293205 | Published Date: 09-Dec-2016 | No. of pages: 74Description
About Human Respiratory Syncytial Virus Drugs
Respiratory syncytial virus (RSV) is a virus that leads to infections in the lungs and the respiratory tract. It commonly affects most children in the ages 2 or below. RSV can also infect adults. In adults and the older population, the symptoms of RSV are mild and similar to that of common cold. Infection with RSV can be severe in certain cases, particularly in premature infants and babies with underlying health conditions. RSV can also become serious in the older population or adults with heart and lung diseases, or any individual with a very weak immune system.
Technavio’s analysts forecast the global human respiratory syncytial virus drugs market to grow at a CAGR of 4.27% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global human respiratory syncytial virus drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent respiratory syncytial virus infections.
The market is divided into the following segments based on geography:
• Europe
• ROW
• US
Technavio's report, Global Human Respiratory Syncytial Virus Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AstraZeneca
• AbbVie
• GSK
• Teva Pharmaceutical
Other prominent vendors
• Ablynx
• ADMA Biologics
• Alnylam Pharmaceuticals
• Ark Biosciences
• Aviragen Therapeutics
• Bavarian Nordic
• Boehringer Ingelheim
• Gilead Sciences
• ImmunoVaccine Technologies
• Johnson & Johnson
• Kyowa Hakko Kirin
• Medivir
• Mucosis
• Mymetics Corporation
• Novavax
• Regeneron Pharmaceuticals
• ReViral
• Vaxart
Market driver
• Novel diagnostic tools increase patient population.
• For a full, detailed list, view our report
Market challenge
• Continuous change in guidelines from healthcare organizations impacts market growth.
• For a full, detailed list, view our report
Market trend
• Emergence of new entrants likely to change market dynamics.
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Respiratory syncytial virus (RSV) is a virus that leads to infections in the lungs and the respiratory tract. It commonly affects most children in the ages 2 or below. RSV can also infect adults. In adults and the older population, the symptoms of RSV are mild and similar to that of common cold. Infection with RSV can be severe in certain cases, particularly in premature infants and babies with underlying health conditions. RSV can also become serious in the older population or adults with heart and lung diseases, or any individual with a very weak immune system.
Technavio’s analysts forecast the global human respiratory syncytial virus drugs market to grow at a CAGR of 4.27% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global human respiratory syncytial virus drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent respiratory syncytial virus infections.
The market is divided into the following segments based on geography:
• Europe
• ROW
• US
Technavio's report, Global Human Respiratory Syncytial Virus Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AstraZeneca
• AbbVie
• GSK
• Teva Pharmaceutical
Other prominent vendors
• Ablynx
• ADMA Biologics
• Alnylam Pharmaceuticals
• Ark Biosciences
• Aviragen Therapeutics
• Bavarian Nordic
• Boehringer Ingelheim
• Gilead Sciences
• ImmunoVaccine Technologies
• Johnson & Johnson
• Kyowa Hakko Kirin
• Medivir
• Mucosis
• Mymetics Corporation
• Novavax
• Regeneron Pharmaceuticals
• ReViral
• Vaxart
Market driver
• Novel diagnostic tools increase patient population.
• For a full, detailed list, view our report
Market challenge
• Continuous change in guidelines from healthcare organizations impacts market growth.
• For a full, detailed list, view our report
Market trend
• Emergence of new entrants likely to change market dynamics.
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
TOC
Tables & Figures
Companies
- PRICE
-
$2500$4000Buy Now